Related references
Note: Only part of the references are listed.Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
Xiao-Feng Liang et al.
LANCET (2010)
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial
Francois Roman et al.
VACCINE (2010)
Response to a Monovalent 2009 Influenza A (H1N1) Vaccine.
Michael E. Greenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine.
Tristan W. Clark et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults
Daniel Wai-Sing Chu et al.
VACCINE (2009)
Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
Isabel Leroux-Roels et al.
PLOS ONE (2008)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
Ten years of experience with the trivalent split-influenza vaccine, Fluarix (TM)
NW Hehme et al.
CLINICAL DRUG INVESTIGATION (2002)
Share Paper
